中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
News
Careers
Investors
Financials & Filing
2025
2024
2023
2022
2021
2020
2019
2018
2025
2024
2023
2022
2021
2020
2019
2018
Poll Results of Annual General Meeting Held on May 22, 2025
2025-05-22
Voluntary Announcement - Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
2025-05-20
Voluntary Announcement - Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
2025-05-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
2025-05-06
Next Day Disclosure Return - Others
2025-04-30
Next Day Disclosure Return - Others
2025-04-29
Next Day Disclosure Return - Others
2025-04-28
Annual Report 2024
2025-04-28
Form of Proxy for the 2025 Annual General Meeting
2025-04-28
Notice of 2025 Annual General Meeting
2025-04-28
«
1
2
3
4
»